DYNE THERAPEUTICS INC (DYN)

What DYNE THERAPEUTICS INC does

Dyne Therapeutics is a biotechnology company focused on discovering and developing precision medicines using its proprietary FORCE (Functional Restoration by Oligonucleotide Complementary Editing) platform. The company is developing therapeutics targeting muscle and neurological diseases where disease pathology involves a genetic defect in the RNA encoding of disease-causing proteins. The FORCE platform is designed to modulate the pre-mRNA of these disease genes, potentially correcting them at the molecular level and restoring functional protein production.

Fundamentals

• Price$24.27 as of 2026-07-09 close
• Market cap$4.0B as of 2026-07-10
• 1-year return+184.0% as of 2026-07-09 close
• ROE-58.3% as of 2026-07-10
• Debt / equity0.18 as of 2026-07-10
• Beta1.11 as of 2026-07-10

Ask why DYN looks like this →

Key risks (from latest filing)

["Clinical development risk: failure to successfully advance product candidates through preclinical studies and clinical trials, particularly given the company's early stage development programs and uncertain outcomes","Regulatory risk: inability to obtain or maintain regulatory approvals for investigational new drug applications (INDs) and subsequent product approvals from the FDA and foreign regulatory authorities","Funding and liquidity risk: dependence on securing additional financing to fund operations and capital requirements, with restrictive loan covenants under the Hercules Capital agreement that could affect the company's financial flexibility"]

See DYN's biggest risks from its latest 10-Q →

Competitors & peers

• Sarepta Therapeutics (SRPT)
• Biogen (BIIB)
• Regeneron Pharmaceuticals (REGN)
• Vertex Pharmaceuticals (VERX)
• Exonics
• Solid Biosciences

Not quite? Describe exactly what you want →